12th October 2021
- 0 comments
Imophoron, a developer of a novel, next generation rapid-response vaccine platform, ADDomer(TM), to combat present and future infectious diseases, has secured £4 million in an oversubscribed fundraising round.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.